Welcome to our dedicated page for Surrozen SEC filings (Ticker: SRZNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Surrozen, Inc. filings document the disclosure record for a biotechnology company developing Wnt pathway-based therapeutics for ophthalmic diseases, along with the capital structure that includes common stock and redeemable warrants. Its 8-K reports include financial results, business updates, pipeline disclosures for programs such as SZN-8141, SZN-8143 and SZN-413, material agreements and changes in board composition.
Surrozen’s proxy materials cover director elections, executive compensation, equity awards, governance matters and shareholder voting items. Registration and offering-related filings describe common stock issuance arrangements, shelf registration mechanics, at-the-market sales agreements, warrant-related security disclosures and related risk and capital-structure information.
Surrozen, Inc. director and 10% owner Tim Kutzkey received a grant of stock options covering 5,550 shares of common stock. The options have an exercise price of $30.14 per share and were awarded at no cost as a compensation-related grant.
The options vest and become exercisable on the anniversary of the May 13, 2026 grant date, provided Kutzkey continues serving on Surrozen’s Board of Directors. After this grant, he holds options for 5,550 underlying shares directly, with no other derivative positions shown in this filing.
Surrozen, Inc. director and 10% owner Tim Kutzkey received a grant of stock options covering 5,550 shares of common stock. The options have an exercise price of $30.14 per share and were awarded at no cost as a compensation-related grant.
The options vest and become exercisable on the anniversary of the May 13, 2026 grant date, provided Kutzkey continues serving on Surrozen’s Board of Directors. After this grant, he holds options for 5,550 underlying shares directly, with no other derivative positions shown in this filing.
Surrozen, Inc. received an updated Schedule 13D/A from venture firm The Column Group and affiliated funds and managers detailing their stakes in the company’s common stock. The filing reports that various Column Group entities and principals Tim Kutzkey and Peter Svennilson collectively report significant beneficial ownership positions, calculated to include shares and warrants exercisable within 60 days.
The Column Group III GP LP reports beneficial ownership of 2,962,544 shares, or 23.6% of the class, while Kutzkey and Svennilson each report 3,824,612 shares, or 29.3%. These amounts reflect current holdings, rights to acquire shares in the second tranche of a private placement, and certain warrants that are exercisable within 60 days, and exclude additional warrants that cannot be exercised within that period due to beneficial ownership limitations.
Surrozen, Inc. received an updated Schedule 13D/A from venture firm The Column Group and affiliated funds and managers detailing their stakes in the company’s common stock. The filing reports that various Column Group entities and principals Tim Kutzkey and Peter Svennilson collectively report significant beneficial ownership positions, calculated to include shares and warrants exercisable within 60 days.
The Column Group III GP LP reports beneficial ownership of 2,962,544 shares, or 23.6% of the class, while Kutzkey and Svennilson each report 3,824,612 shares, or 29.3%. These amounts reflect current holdings, rights to acquire shares in the second tranche of a private placement, and certain warrants that are exercisable within 60 days, and exclude additional warrants that cannot be exercised within that period due to beneficial ownership limitations.
Surrozen, Inc. ownership filing: Nantahala Capital Management, LLC and its managing members Wilmot B. Harkey and Daniel Mack report beneficial ownership of 225,772 shares of Common Stock as of March 31, 2026. The filing states these 225,772 shares may be acquired within sixty days through exercise of convertible securities, representing 2.14% of the class. The Reporting Persons disclose shared voting and dispositive power over the 225,772 shares and no sole voting or dispositive power.
Surrozen, Inc. ownership filing: Nantahala Capital Management, LLC and its managing members Wilmot B. Harkey and Daniel Mack report beneficial ownership of 225,772 shares of Common Stock as of March 31, 2026. The filing states these 225,772 shares may be acquired within sixty days through exercise of convertible securities, representing 2.14% of the class. The Reporting Persons disclose shared voting and dispositive power over the 225,772 shares and no sole voting or dispositive power.
Surrozen, Inc. Schedule 13G/A: a group led by Venrock-related entities and two individuals reports aggregated beneficial ownership of 9.99% of common stock as of March 31, 2026. The filing states 11,490,000 shares outstanding as of March 31, 2026 and 572,069 shares issuable upon exercise of warrants.
The group holds a mix of common shares, Pre-Funded Warrants and Series E Warrants and notes a Beneficial Ownership Blocker that prevents exercises that would increase ownership above 9.99%. Each Reporting Person is reported at the 9.99% level and certain exercises are capped at 1,205,000 shares.
Surrozen, Inc. Schedule 13G/A: a group led by Venrock-related entities and two individuals reports aggregated beneficial ownership of 9.99% of common stock as of March 31, 2026. The filing states 11,490,000 shares outstanding as of March 31, 2026 and 572,069 shares issuable upon exercise of warrants.
The group holds a mix of common shares, Pre-Funded Warrants and Series E Warrants and notes a Beneficial Ownership Blocker that prevents exercises that would increase ownership above 9.99%. Each Reporting Person is reported at the 9.99% level and certain exercises are capped at 1,205,000 shares.
Surrozen, Inc. Schedule 13G/A amendment: Reporting Persons led by TCG Crossover II/III and Chen Yu amended their prior filing to disclose beneficial ownership positions in the Issuer's Common Stock. Each of TCG Crossover II and TCG Crossover III is shown with 736,554 shares (representing 6.3%). Chen Yu is shown with 1,473,101 shares (representing 12.7%), consisting of the positions held by the two TCG funds. The filing cites 11,610,371 shares outstanding as of May 4, 2026 (and May 1, 2026 in one instance) as the basis for percentage calculations. The Reporting Persons disclaim group status and attribute record ownership to the TCG entities; Chen Yu is disclosed as sole managing member of the GP entities.
Surrozen, Inc. Schedule 13G/A amendment: Reporting Persons led by TCG Crossover II/III and Chen Yu amended their prior filing to disclose beneficial ownership positions in the Issuer's Common Stock. Each of TCG Crossover II and TCG Crossover III is shown with 736,554 shares (representing 6.3%). Chen Yu is shown with 1,473,101 shares (representing 12.7%), consisting of the positions held by the two TCG funds. The filing cites 11,610,371 shares outstanding as of May 4, 2026 (and May 1, 2026 in one instance) as the basis for percentage calculations. The Reporting Persons disclaim group status and attribute record ownership to the TCG entities; Chen Yu is disclosed as sole managing member of the GP entities.
Surrozen, Inc. amendment to a Schedule 13G/A reports that each of 5AM Ventures VII, L.P., 5AM Partners VII, LLC, Andrew J. Schwab and Kush Parmar beneficially own 1,162,500 shares, representing 9.5% of common stock based on 11,486,707 shares outstanding as of March 18, 2026. The filing discloses that Ventures VII directly holds 387,500 shares plus warrants exercisable for 77,500 shares, and has rights to purchase an additional 465,000 shares and warrants exercisable for 232,500 shares upon a regulatory milestone or under limited post-termination windows.
The filing states that Partners VII is the general partner of Ventures VII and that Schwab and Dr. Parmar are managing members of Partners VII, sharing voting and dispositive power over the securities held by Ventures VII. The reporting persons disclaim status as a group.
Surrozen, Inc. amendment to a Schedule 13G/A reports that each of 5AM Ventures VII, L.P., 5AM Partners VII, LLC, Andrew J. Schwab and Kush Parmar beneficially own 1,162,500 shares, representing 9.5% of common stock based on 11,486,707 shares outstanding as of March 18, 2026. The filing discloses that Ventures VII directly holds 387,500 shares plus warrants exercisable for 77,500 shares, and has rights to purchase an additional 465,000 shares and warrants exercisable for 232,500 shares upon a regulatory milestone or under limited post-termination windows.
The filing states that Partners VII is the general partner of Ventures VII and that Schwab and Dr. Parmar are managing members of Partners VII, sharing voting and dispositive power over the securities held by Ventures VII. The reporting persons disclaim status as a group.
Surrozen, Inc. ownership is reported jointly by Boxer Capital Management, LLC and related entities. The filing states the Reporting Persons beneficially own 766,318 shares of common stock as of March 31, 2026, representing 6.67% of the class based on 11,486,707 shares outstanding as of March 19, 2026.
The cover data shows shared voting and shared dispositive power for the 766,318 shares; signatures are dated May 15, 2026.
Surrozen, Inc. ownership is reported jointly by Boxer Capital Management, LLC and related entities. The filing states the Reporting Persons beneficially own 766,318 shares of common stock as of March 31, 2026, representing 6.67% of the class based on 11,486,707 shares outstanding as of March 19, 2026.
The cover data shows shared voting and shared dispositive power for the 766,318 shares; signatures are dated May 15, 2026.
Surrozen, Inc. reports beneficial ownership of 525,639 shares, representing 4.5% of its common stock. The amount consists of 195,981 shares of common stock and 329,658 shares issuable upon exercise of warrants. Shares outstanding were 11,486,707 as of March 19, 2026, and warrant counts include Series A, Series B and Series E warrants; ownership is subject to a 9.9% beneficial ownership limitation.
Surrozen, Inc. reports beneficial ownership of 525,639 shares, representing 4.5% of its common stock. The amount consists of 195,981 shares of common stock and 329,658 shares issuable upon exercise of warrants. Shares outstanding were 11,486,707 as of March 19, 2026, and warrant counts include Series A, Series B and Series E warrants; ownership is subject to a 9.9% beneficial ownership limitation.
Surrozen, Inc. director Mace Rothenberg received a grant of stock options as part of board compensation. The award covers 5,550 options to purchase Common Stock at an exercise price of $30.14 per share. The options vest and become exercisable on the anniversary of the May 13, 2026 grant date, conditioned on continuous service as a director, and expire on May 12, 2036. Following this grant, Rothenberg holds 5,550 options directly.
Surrozen, Inc. director Mace Rothenberg received a grant of stock options as part of board compensation. The award covers 5,550 options to purchase Common Stock at an exercise price of $30.14 per share. The options vest and become exercisable on the anniversary of the May 13, 2026 grant date, conditioned on continuous service as a director, and expire on May 12, 2036. Following this grant, Rothenberg holds 5,550 options directly.
Surrozen, Inc./DE director David J. Woodhouse received a grant of 5,550 stock options, giving him the right to buy 5,550 shares of Common Stock. The options have a conversion or exercise price of $30.14 per share and expire on May 12, 2036. According to the terms, the options vest and become exercisable on the anniversary of the grant date, subject to his continuous service as a director. After this grant, he holds 5,550 director stock options directly, and this filing reflects a compensation-related award rather than an open-market share purchase or sale.
Surrozen, Inc./DE director David J. Woodhouse received a grant of 5,550 stock options, giving him the right to buy 5,550 shares of Common Stock. The options have a conversion or exercise price of $30.14 per share and expire on May 12, 2036. According to the terms, the options vest and become exercisable on the anniversary of the grant date, subject to his continuous service as a director. After this grant, he holds 5,550 director stock options directly, and this filing reflects a compensation-related award rather than an open-market share purchase or sale.